Cladribine in the Treatment of Chronic Lymphocytic Leukemia

References

• Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952–956
   PubMed Web of Science ®Google Scholar
• Bryson H. M., Sorkin E. M. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993; 46: 872–894
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Kaye J., Ullman B., Martin D. W., Jr., Robins R. K., Montgomery J. A. Deox-ycytidine kinase mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl. Acad. Sci. USA 1980; 77: 6865–6869
   PubMed Web of Science ®Google Scholar
• Kazimierczuk Z., Cottam H. B., Revankar G. R., Robins R. K. Synthesis of 2-deoxynucleosides via a novel direct sterospecific sodium salt glycosylation procedure. J. Am. Chem. Soc. 1984; 106: 6379–6382
   Web of Science ®Google Scholar
• Carson D. A., Kay J., Seegmiller J. E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase (s). Proc. Natl. Acad. Sci. USA 1977; 74: 5677–5681
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–743
   PubMed Web of Science ®Google Scholar
• Avery T. L., Rehg J. E., Lumm W.C, Harwood F. C., Santana V. M., Blakley R. L. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res. 1989; 49: 4972–4978
   PubMed Web of Science ®Google Scholar
• Seto S., Carrera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Griffig J., Koob R., Blakley R. L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989; 49: 6923–6928
   PubMed Web of Science ®Google Scholar
• Warzocha K., Fabianowska-Majewska K., Btoński J., Krykowski E., Robak T. 2-chlorodeoxyadenosine inhibits activity of adenosine deaminase and s-adenosyl-homocysteine hydrolase in patients with chronic lymphocytic leukemia. Eur. J. Cancer 1997; 33: 170–173
   Web of Science ®Google Scholar
• Robertson L.E., Chubb S., Meyn R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Castejon R., Vargas J. A., Briz M., Berrocal E., Romero Y., Gea-Banacloche J. C., Fernandez M. N., Durantez A. Induction of apoptosis by 2-chlorodeoxyadenosine in B-cell chronic lymphocytic leukemia. Leukemia 1997; 11: 1253–1257
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. USA. 1984; 81: 2232–2236
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Robak T., Btasińska-Morawiec M., Btoński J., Hellmann A., Haraburda K., Konopka L., Kotlarek-Haus S., Potoczek S., Hansz J., Dmoszyńska A., Urasiński I., Zdziarska B., Dwilewicz-Trojaczek J., Holowiecki J., Skotnicki A. B. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur. J. Haematol. 1999; 62: 49–56
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
   PubMed Web of Science ®Google Scholar
• Robak T., Blasińska-Morawiec M., Krykowski E., Kasznicki M., Pfuzańska A., Potemski P., Hellmann A., Zaucha J. M., Lewandowski K., Dmoszyńska A., Hansz J., Komarnicki M., Konopka L., Duiiyński T., Ceglarek B., Sikorska A., Kotlarek-Haus S., Mazur G., Urasiński I., Zdziarska B., Maj S., Kopec I., Skotnicki A. B., Dwilewicz-Trojaczek J., Kuratowska Z, Grieb P. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymphoma. 1996; 22: 509–514
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., Carson D. A., Thurston D., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Robak T., Góra-Tybor J., Krykowski E., Walewski J. A., Borawska A., Pluzańska A., Potemski P., Hellmann A., Zaucha J. M., Konopka L., Ceglarek B., Duiiyński T., Sikorskia A., Michalak K., Urasinski I., Opalińska J., Dmoszyńska A., Adamczyk-Cioch M. D., Kuratowska Z., Dwilewicz-Trojaczek J., Boguradzki P., Dereń M., Maj S., Grieb P. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk. Lymphoma 1997; 26: 99–105
   PubMed Web of Science ®Google Scholar
• Kong L. R., Samuelson E., Rosen S. T., Roenigk H. H., Jr., Tallman M. S., Rademaker A. W., Kuzel T. M. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk. Lymph. 1997; 26: 89–97
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Kantarjian H., Weber D., O'Brien S., Estey E., Delasalle K., Rose Cabanillas F.E., Keating M., Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J. Clin. Oncol. 1994; 12: 2694–2698
   PubMed Web of Science ®Google Scholar
• Hellmann A., Lewandowski K., Zaucha J. M., Bieniaszewska M., Halaburda K., Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur. J. Haematol. 1999; 63: 35–41
   PubMed Web of Science ®Google Scholar
• Liliemark J., Juliusson G. On the pharmacokinetics of 2-chloro-2′deoxyadenosine in humans. Cancer Res. 1991; 51: 5570–5572
   PubMed Web of Science ®Google Scholar
• Santana V. M., Mirro J., Jr., Kearns C., Schell M. J., Crom W., Blakley R. L. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin Oncol. 1992; 10: 364–370
   PubMed Web of Science ®Google Scholar
• Santana V. M., Mirro J., Jr., Harwood F. C., Cherrie J., Schell M., Kalwinsky D., Blakley R. L. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J. Clin. Oncol. 1991; 9: 416–422
   PubMed Web of Science ®Google Scholar
• Liliemark J., Albertioni F., Hassan M., Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 1992; 10: 1514–1518
   PubMed Web of Science ®Google Scholar
• Juliusson G., Heldal D., Hippe E., Hedenus M., Malm C., Wallman K., Stolt C. M., Evensen S. A., Albertioni F. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. 1995; 13: 989–995
   PubMed Web of Science ®Google Scholar
• Lauria F., Boachia M., Marotta G., Respadori D., Zinzani P. L., Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84: 22–25
   PubMed Web of Science ®Google Scholar
• Albertioni F., Juliusson G., Liliemark J. On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA). The influence of food and omeprazole. Eur. J. Clin. Pharmacol. 1993; 44: 579–582
   PubMed Web of Science ®Google Scholar
• Albertioni F., Juliusson G., Liliemark J. On the pharmacokinetics of 2-chloro'-deoxyadenosine (CdA) and renal excretion after intravenous and oral administration. Proc. Am. Soc. Clin. Oncol. Ann. Meet. 1994; 13: A421, (abstract)
   Google Scholar
• Albertioni F., Lindemalm S., Reichelova V., Pettersson B., Eriksson S., Juliusson G., Liliemark J. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin. Cancer Res. 1998; 4: 653–658
   PubMed Web of Science ®Google Scholar
• Arner E. S., Spasokoukotskaja T., Juliusson G., Liliemark J., Eriksson S. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. Br. J. Haematol. 1994; 87: 715–718
   PubMed Web of Science ®Google Scholar
• Kawasaki H., Carrera C. J., Piro L. D., Saven A., Kipps T. J., Carson D. A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597–601
   PubMed Web of Science ®Google Scholar
• Begleiter A., Verburg L., Ashique A., Lee K., Israels L. G., Mowat M. R., Johnson J. B. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875–1881
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation. Semin. Hematol. 1998; 35(suppl 3)14–21
   PubMed Web of Science ®Google Scholar
• Bergman L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997; 11((suppl 2))S29–S39
   PubMed Web of Science ®Google Scholar
• Saven Carrera A.C.J., Carson D. A., Beutler E., Piro L. D. 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma 1991; 5: 133–138, (suppl)
   PubMed Web of Science ®Google Scholar
• Robak T., Btoński J.Z., Kasznicki M., Konopka L., Ceglarek B., Dmoszyńska A., Soroka-Wojtaszko M., Skotnicki A. B., Nowak W., Dwilewicz-Trojaczek J., Tomaszewska A., Hellmann A., Lewandowski K., Kuliczkowski K., Potoczek S., Zdziarska B., Hansz J., Kroll R., Komarnicki M., Hotowiecki J., Grieb P. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia — an updated results of the multicenter study of 378 patients. Br. J. Haematol. 2000; 108: 357–368
   PubMed Web of Science ®Google Scholar
• Catovsky D., Fooks J., Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A raport from the MRC Working Party on Leukaemia in Adults CLL trial. Br. J.Haematol. 1989; 72: 141–149
   PubMed Web of Science ®Google Scholar
• Anaissie E. J., Konotoyiannis D. P., O'Brien S., Kantarjian H., Robertson L., Lerner S., Keating M. J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med. 1998; 129: 559–566
   PubMed Web of Science ®Google Scholar
• Robak T., Blasińska-Morawiec M., Bloński J.Z., Dmoszyńska A. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 1999; 34: 151–157
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Beran M., Smith T., Koller Estey C.E., Robertson L. E., Lerner S., Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis — derived model for response to treatment. Blood 1993; 82: 1695–1700
   PubMed Web of Science ®Google Scholar
• Robak T., Btoński J.Z., Kasznicki M., Krykowski E., Dmoszyńska A., Konopka L., Hellmann A., Dwilewicz-Trojaczek J. Retrospective analysis of survival of 541 chronic lymphocytic leukemia (CLL) patients treated with 2-CdA (Cladribine) as 1st or 2nd line and treated without 2-CdA. Blood 1999; 94((suppl 1 part 1))314a, (abstr. 1403)
   Google Scholar
• Tallman M. S., Hakimian D., Zanzig C., Hogan D. K., Rademaker A., Rose E., Variakojis D. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 1995; 13: 983–988
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. Long term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann. Oncol. 1996; 7: 373–379
   PubMed Web of Science ®Google Scholar
• Rondelli D., Lauria F., Zinzani P. L., Raspadori D., Ventura M. D., Galieni P., Birtolo S., Forconi F., Algeri R., Tura S. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur. J. Haematol. 1997; 58: 46–50
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R. H., Kosty M., Beutler E., Piro L. D. 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1995; 13: 570–574
   PubMed Web of Science ®Google Scholar
• Juliusson G., Christiansen I., Hansen M. M., Johnson S., Kimby E., Elmhorn-Rosenborg A., Liliemark J. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 1996; 14: 2160–2166
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Wollins E., Jain V., Schiller G., Shepherd J., Silver R., Peterson L. Leustatin in the treatment of patients with previously untreated chronic lymphocytic leukemia. Blood 1997; 90((suppl 1))578a, (abstr)
   PubMed Web of Science ®Google Scholar
• Delannoy A., Martial P., Gala J. L., Deneys K., Ferrant A., Bosly A., Schieff J. M., Michaux J. L. 2-chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130–1135
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Therapy for previously untreated chronic lymphocytic leukemia: a revaluation. Semin Hematol. 1998; 35((3 suppl 3))14–21
   PubMed Web of Science ®Google Scholar
• Rai K. R., Peterson B., Elias L., Shepherd L., Hines J., Nelson D., Cheson B., Kolitz J., Schiffer C. A. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG inter-group study. Blood 1996; 88: 141a, (abstr 522)
   Web of Science ®Google Scholar
• Johnson S., Smith A. G., Leffler H., Osby E., Juliusson G., Emmerich B., Wyld P. J., Hiddemann W., French Cooperative Group on CLL. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438
   PubMed Web of Science ®Google Scholar
• Spriano M., Chiurazzi F., Cassibba V., Montillo M., Liso V., Mazza P., Molica S., Bruni R., Clavio M., Gobbi M., Santini G. Multicentre prospective randomized trial of fludarabine vs chlorambucil and prednisone in previously untreated patients with active B-chronic lymphocytic leukaemia (B-CLL): conclusive report. Haematologica 1999; 84(259), (abstr. SS 1091)
   PubMedGoogle Scholar
• Robak T., Bloński J.Z., Kasznicki M., Biasińska-Morawiec M., Dmoszyńska A., Skotnicki A. B., Konopka L., Hellmann A., Dwilewicz-Trojaczek J., Zdziarska B., Maj S., Grieb P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in B-CLL VIII International Workshop on CLL. 29–31 October 1999, Paris 1999; 50, (abstr. 81)
   Google Scholar
• Morabito F., Stelitano C., Callea I., Filangeri M., Oliva B., Sculli G., Callea V., Nobile F., Briugatelli M. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224–231
   PubMed Web of Science ®Google Scholar
• Begleiter A., Verburg L., Ashique A., Lee K., Israels L. G., Mowat M. R., Johnston I. B. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875–1881
   PubMed Web of Science ®Google Scholar
• Juliusson G., Elmhorn-Rosenborg A., Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1992; 327: 1056–1061
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Estey E., Koller C., Robertson B., Beran M., Andreef M., Pierce S., Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N. Engl. J. Med. 1994; 330: 319–322
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R. H., Kosty M., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1995; 13: 570–574
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA — induced remission: no acquired resistance. Leuk. Lymph. 1994; 13: 75–80
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Beran M., Koller C., Talpaz M., Lerner S., Keating M. J. Fludarabine and granulocyte colony — stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631–1635
   PubMed Web of Science ®Google Scholar
• Juliusson G., Lenkei R., Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672–3681
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Infections and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 1995; 13: 2431–2448
   PubMed Web of Science ®Google Scholar
• Van Den Neste E., Delannoy A., Vandercam B., Bosly A., Ferrant A., Mineur P., Montfort L., Martiat P., Straetmans N., Filleul B., Michaux J. L. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol. 1996; 56: 235–240
   PubMed Web of Science ®Google Scholar
• Betticher D. C., Ratschiller D., Schmitz Hsu, von S-F, Rohr A., Hess U., Zulian G., Wernli M., Tichelli A., Tobler A., Fey M.F., Cerny T. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 1998; 9: 721–726
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Vena D. A., Foss F. M., Sorensen J. M. Neurotoxicity of purine analogs: a review. J. Clin. Oncol. 1994; 12: 2216–2228
   PubMed Web of Science ®Google Scholar
• Warzocha K., Fabianowska-Majewska K., Robak T. Neurotoxic effects of new purine analogs. Acta Haematol. Pol. 1998; 29((suppl 2))13–23
   Google Scholar
• Bastion Y., Coiffier B., Dumontet C., Espinouse D., Bryon P. A. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann. Oncol. 1992; 3: 171–172
   PubMed Web of Science ®Google Scholar
• Robak T., Blasińska-Morawiec M., Krykowski E., Hellmann A., Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur. J. Haematol. 1997; 58: 109–113
   PubMed Web of Science ®Google Scholar
• Chasty R. C., Myint H., Oscier D. G., Orchard J. A., Bussutil D. P., Hamon M. D., Prentice A. G., Copplestone J. A. Leuk. Lymphoma. 1998; 29: 391–398
   PubMed Web of Science ®Google Scholar
• Fleischman R. A., Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am. J. Hematol. 1995; 48: 293
   PubMed Web of Science ®Google Scholar
• Adkins J. C., Peters D. H., Markham A. Fludarabine: An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005–1037
   PubMed Web of Science ®Google Scholar
• Robak T., Biasińska-Morawiec M., Krykowski E., Hellmann A., Lewandowski K., Dmoszyńska A., Adamczyk-Cioch M., Kazimierczak M., Trepińska E., Dwilewicz-Trojaczek M., Kuratowska Z., Skotnicki A. B., Nowak W. S., Zdziarska B., Urasiński I. 2-Chlorodeoxyadenosine (cladribine) — related eosinophilia in patients with lymphoproliferative diseases. Eur. J. Haematol. 1997; 59: 216–220
   PubMed Web of Science ®Google Scholar
• Larfars G., Uden-Blohme A. M., Samuelsson J. Fludarabine as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies. Br. J.Haematol. 1996; 94: 709–712
   PubMed Web of Science ®Google Scholar
• Robak T., Bjasińska-Morawic M., Krykowski E. Transient eosinophilia in a patient with hairy cell leukaemia treated with 2-chlorodeoxyadenosine. Acta Haematol. Pol. 1992; 23: 285–290
   PubMedGoogle Scholar
• Kroft S. H., Tallman M. S., Shaw J. M., Thangavelu M., Peterson L. C. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia 1997; 11: 170
   PubMed Web of Science ®Google Scholar
• Van Den Neste E., Louviaux I., Michaux J. L., Delannoy A., Michaux L., Hagemeijer A., Scheiff J.M., Bosly A., Straetmans N., Ferrant A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br. J. Haematol. 1999; 105: 268–270
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Vena D., Friedlin B. The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc. Soc. Soc. Clin. Oncol. 1997; 16(15a (abstr 52))
   Google Scholar
• Cheson B. D., Vena D. A., Barrett J., Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J. Clin. Oncol. 1999; 17: 2454–2460
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Huoh Y. O., Butler J. J., Pugh W. C., Hirsch-Ginsberg C., Stass S., Kantarjian H., Keating M. J. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic immunophenotypic and molecular analysis. Blood 1992; 80: 29–36
   PubMed Web of Science ®Google Scholar
• Robak T., Btoński J.Z., Urbańska-Ryś H., Btasińska-Morawiec M., Skotnicki A. B. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999; 13: 518–523
   PubMed Web of Science ®Google Scholar
• Crook T. R., Souhami R. L., Lean Mc A.E. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 1986; 46: 5029–5034
   PubMed Web of Science ®Google Scholar
• Van Den Neste E., Boutemps F., Delacauw A., Cardoen S., Louviaux I., Scheiff J. M., Gillis E., Leveugle P., Deneys V., Ferrant A., Van den Berghe G. Potentiation of antinumour effect of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine. Leukemia 1999; 13: 918–925
   PubMed Web of Science ®Google Scholar
• Góra-Tybor J., Robak T. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol. Pol. 1993; 24: 177–182
   PubMedGoogle Scholar
• Laurencet F. M., Zulian G. B., Guetty-Alberto M., Iten P. A., Betticher D. C., Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br. J.Cancer 1999; 79: 1215–1219
   PubMed Web of Science ®Google Scholar
• Weber D. M., Delasalle K., Gavino M., Wood A., Cabanillas F., Alexanian R. Primary treatment of Waldentsrom's macroglobulinemia with subcutaneous 2-chlorodeoxyadenosine and oral cyclophosphamide. Blood 1997; 90((suppl 1 pl))357a, (abstract 1592)
   Google Scholar
• O'Brien S., Kantarjian H., Beran M., Freireich E., Komblau S., Roller C., Lerner S., Gilbreath J., Keating M. Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL). Blood 1996; 88(suppl 1)480a, (abstrac 1910)
   Google Scholar
• Frewin R., Turner D., Tighe M., Daries M., Rule S., Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br. J.Haematol. 1999; 104: 612–613
   PubMed Web of Science ®Google Scholar
• Begleiter A., Wang H., Verburg L., Lee K., Israels L. G., Mowat M. R., Johnson J. B. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996; 10: 1959–1965
   PubMed Web of Science ®Google Scholar
• Johnston J. B., Verburg L., Shore T., Williams M., Israels L. G., Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 1994; 8((suppl 1))S140–143
   PubMed Web of Science ®Google Scholar
• Hoffman M., Xu J. C., Lesser M., Rai K. Cytotoxicity of 2-chlorodeoxyadenosine (cladribine, 2-CdA) in combination with other chemotherapy drugs against two lymphoma cell lines. Leuk. Lymphoma. 1999; 33: 141–145
   PubMed Web of Science ®Google Scholar
• Tefferi A., Witzig T. E., Reid J. M., Li C Y, Ames M. M. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J. Clin. Oncol. 1994; 12: 569–574
   PubMed Web of Science ®Google Scholar
• Weiss M., Spiess T., Berman E., Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994; 8: 1290–1293
   PubMed Web of Science ®Google Scholar
• Rai K. R., Peterson B., Kolitz J., Elias L., Shepherd L., Hines J., Cheson B., Schiffer C. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized inter-group study. Blood 1995; 86: 607a, (suppl) (abstract 2414)
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Hagemeister F. B., Romaguera J. E., Sarris A.H. Pate, Younes O.A., Swan F., Keating M., Cabanillas F. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol. 1996; 14: 1262–1268
   PubMed Web of Science ®Google Scholar
• Saven A., Lee T., Kosty M., Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 1996; 14: 2139–2144
   PubMed Web of Science ®Google Scholar
• Robak T., Góra-Tybor J., Urbańska-Ryś H., Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk. Lymphoma. 1999; 32: 359–363
   PubMed Web of Science ®Google Scholar
• Robak T., Góra-Tybor J., Chojnowski K. Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies. Haematologica 2000; 85: 215–216
   PubMed Web of Science ®Google Scholar
• Roberston L. E., O'Brien S., Kantarjian H., Roller C., Beran M., Andreef M., Lerner S., Keating M. J. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 943–945
   PubMed Web of Science ®Google Scholar
• Van Den Neste E., Martat P., Mineur P., Delannoy A., Doyen C., Zenebergh A., Michaux J. L., Ferrant A. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann Hematol. 1998; 76: 19–23
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Keating M. J., Chuorallach A., Plunkett W. Chlorodeoxyadenosine and arabinosyl cytosine in patients with acute myelogenous leukemia: pharmacokinetics; pharmacodynamic and molecular interactions. Blood 1996; 87: 256–264
   PubMed Web of Science ®Google Scholar
• Szmigielska A., Góra-Tybor J., Robak T. Influence of 2-chlorodeoxyadenosine alone or in combination with cytosine arabinoside on murine leukemias L1210 and P388. Cancer, J. 1996; 9: 319–322
   Web of Science ®Google Scholar
• Marańda E., Szmigielska A., Robak T. Additive action of gemcitabine (2′,2′-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. Cancer Invest. 1999; 17: 95–101
   PubMed Web of Science ®Google Scholar
• Tosi P., Pellacani A., Zinzani P. L., Magangoli M., Visani G., Tura S. In vitro study of the combination gemcitabine + fludarabine of freshly isolated chronic lymphocytic leukemia cells. Haematologica 1999; 84: 794–798
   PubMed Web of Science ®Google Scholar
• Drexler H. G., Gignac S. M., Jones R.A., Scott C. S., Petti G.R., Hoffbrand A. V. Bryostatin 1 induces differentation of B-chronic lymphocytic leukemia cells. Blood 1998; 74: 1747–1757
   Google Scholar
• Mohammad R. M., Katato K., Almachy V. P., Wall N., Liu K., Schultz C. P., Mantsch H. H., Varterasian M., Al-Katib A. M. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clin. Cancer Res. 1998; 4: 445–453
   PubMed Web of Science ®Google Scholar
• Góra-Tybor J., Robak T. Does-interleukin-2 endance the antinumor activity of 2-chlorodeoxyadenosine?. Cancer J. 1997; 10: 171–174
   Web of Science ®Google Scholar
• Robak T., Korycka A., Góra-Tybor J. The interaction of 2-chlorodeoxyadenosine (2-CdA) and interferon-α (IFN-α) on normal and myeloid leukemia hematopoiesis in vitro. Leuk. Res. 1994; 18: 275–281
   PubMed Web of Science ®Google Scholar
• Korycka A., Robak T. The influence of recombinant human tumor necrosis factor-α and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro. Leuk. Res. 1997; 21: 857–865
   PubMed Web of Science ®Google Scholar
• Bowen A. L., Zomas A., Emmett E., Matutes M. J., Dyer M. J., Catovsky D. Subcutaneous CAMPATH-1H in fludarabine — resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J.Haematol. 1997; 96: 617–619
   PubMed Web of Science ®Google Scholar